Traveling to UK with Peptides: The Rules

Travelling to the UK with prescription medicines and research peptides raises two separate regulatory questions. The first is straightforward: UK law imposes clear documentation requirements for controlled drugs brought across the border. The second is murkier: peptides such as CJC-1295 and ipamorelin are not licensed medicines in the UK, which puts them in a different category from a prescription testosterone product. This article explains what each regime looks like, using the UK government's published guidance as the starting point.

What UK rules say about travelling with prescription medicines

The UK government's guidance on taking medicine in or out of the country is explicit: if your medicine contains a controlled drug, you must carry it in your hand luggage when entering or leaving the UK^[1]. You also need to be able to prove the medicine is yours. For UK residents departing, that means either a current prescription or a letter from the prescribing doctor. For non-UK residents arriving, the documentation bar is a bit higher: a letter of proof that includes your name, your travel dates, the full medication list with quantities and doses, and the prescriber's signature^[1]. The maximum quantity allowed through is three months' supply; anything above that will be confiscated^[1].

Testosterone is relevant here because it is a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001. UK law lists testosterone alongside other anabolic steroids in this schedule^[2]. That means it falls within the controlled drugs framework, not outside it. Someone travelling with testosterone on a legitimate prescription needs to carry the documentation the gov.uk guidance specifies, and keep the medicine in hand luggage, not in checked bags.

The TravelHealthPro factsheet published by the UK Health Security Agency also recommends carrying original pharmacy packaging and copies of the prescription alongside any doctor letter, to make the medicine's provenance clear at the border if asked.

The Netherlands transit dimension

Amsterdam Schiphol is one of Europe's busiest transit hubs, and it sits inside the Schengen Area. Whether a transit stop triggers a customs inspection depends on several factors: whether you pass through the international transit zone without clearing Dutch border control, the airline routing, and whether baggage is checked through to the final destination. For most connecting flights between non-Schengen points, passengers in the international transit zone are not formally entering the Netherlands, and Dutch customs rules do not apply in the same way as for arrivals.

That said, the gov.uk guidance notes that a Schengen Certificate exists as documentation for carrying certain controlled medicines across Schengen member states^[1]. The guidance also notes a limit: a Schengen Certificate cannot be used to bring Schedule 1 drugs into the UK, which is a reminder that the certificate has scope restrictions. For travellers transiting Amsterdam, the UK Foreign, Commonwealth and Development Office recommends checking the rules for any intermediate country via that country's embassy before travel. The Dutch government's position on transit passengers carrying controlled medicines is best confirmed with the Netherlands embassy or the Dutch CBG medicines authority before departure.

Where CJC-1295 and ipamorelin sit in UK regulatory terms

CJC-1295 and ipamorelin are growth-hormone-releasing peptides. Neither appears in the MHRA's register of licensed medicines for the UK. The MHRA's products database does not list either substance as an approved medicine^[3]. That absence matters because it places them outside the licensed medicines framework entirely: there is no marketing authorisation, no approved patient information leaflet, and no defined indication for human use.

Equally, neither CJC-1295 nor ipamorelin appears in the schedules of the Misuse of Drugs Act 1971 or in the Misuse of Drugs Regulations 2001. They are not controlled drugs in the UK legal sense. The controlled drug framework that applies to testosterone does not apply to these peptides in the same way. What does apply is the broader medicines licensing regime: introducing an unlicensed product into the UK for human use can raise legal questions under the Human Medicines Regulations 2012, even when the product is not a controlled drug.

In practice, the import picture for unlicensed peptides is genuinely uncertain. UK Border Force does not publish a list of peptides that will or will not be confiscated. The safe characterisation of the position is that CJC-1295 and ipamorelin are not licensed medicines and not controlled drugs in UK law, but that bringing them into the UK for human administration sits in a legally ambiguous space that is different from, and not governed by, the controlled drugs documentation requirements.

Documentation travellers typically carry

For the controlled drug part of the picture, the gov.uk guidance sets out what documentation is expected. For a traveller with a legitimate testosterone prescription, the standard documentation package includes: a current prescription naming the patient, the medicine, the dose and the prescribing clinician; a covering letter from the prescribing doctor that includes the travel dates and confirms the medicine is for personal use; and original pharmacy packaging with the dispensing label still attached^[1]. The TravelHealthPro factsheet adds that generic (non-brand) medicine names in the letter are useful because customs officers often work from non-proprietary names^[4].

For any country where the traveller has a layover, the UK guidance is consistent: check the destination and transit country rules via the relevant embassy before travel. Regulatory positions on controlled medicines differ between countries, and a document that satisfies UK Border Force may not satisfy customs at the transit point.

For peptides that are not licensed medicines, there is no documentation framework that resolves the ambiguity. The absence of a prescription-or-letter requirement reflects the absence of a licensed medicine, not a green light. Travellers considering carrying unlicensed peptides across international borders should seek advice from a lawyer or the relevant customs authority before departure, not after. This is an area where the regulations do not provide a tidy answer, and PeptideMethods does not provide legal advice.

For more on the UK regulatory position for specific peptides, see the CJC-1295 peptide page and the ipamorelin peptide page. Country-specific regulatory detail for the UK is on the UK regulation hub.